324 related articles for article (PubMed ID: 32185681)
41. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
42. Pembrolizumab for the treatment of melanoma.
Kumar SS; McNeil CM
Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
[TBL] [Abstract][Full Text] [Related]
43. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
Singh AK; Porrata LF; Aljitawi O; Lin T; Shune L; Ganguly S; McGuirk JP; Abhyankar S
Bone Marrow Transplant; 2016 Sep; 51(9):1268-70. PubMed ID: 27111048
[No Abstract] [Full Text] [Related]
44. Toripalimab: First Global Approval.
Keam SJ
Drugs; 2019 Apr; 79(5):573-578. PubMed ID: 30805896
[TBL] [Abstract][Full Text] [Related]
45. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
46. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
47. Current treatment and immunotherapy of Hodgkin's lymphoma.
Klimm B; Schnell R; Diehl V; Engert A
Haematologica; 2005 Dec; 90(12):1680-92. PubMed ID: 16330443
[TBL] [Abstract][Full Text] [Related]
48. Haematological cancer: PD-1 blockade: opening the door to attack.
Hutchinson L
Nat Rev Clin Oncol; 2015 Feb; 12(2):65. PubMed ID: 25533946
[No Abstract] [Full Text] [Related]
49. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
50. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
51. [Checkpoint inhibitors in Hodgkin lymphoma].
Sasse S; Momotow J; Engert A
Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
[TBL] [Abstract][Full Text] [Related]
52. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
Gormley NJ; Pazdur R
N Engl J Med; 2018 Nov; 379(19):1791-1795. PubMed ID: 30403935
[No Abstract] [Full Text] [Related]
54. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
55. PD-1 inhibitor approved for melanoma.
Cancer Discov; 2014 Nov; 4(11):1249. PubMed ID: 25367933
[No Abstract] [Full Text] [Related]
56. Envafolimab: First Approval.
Markham A
Drugs; 2022 Feb; 82(2):235-240. PubMed ID: 35122636
[TBL] [Abstract][Full Text] [Related]
57. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
58. Bladder cancer in 2017: Advancing care through genomics and immune checkpoint blockade.
Galsky MD
Nat Rev Urol; 2018 Feb; 15(2):71-72. PubMed ID: 29182606
[No Abstract] [Full Text] [Related]
59. Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Yu T; Liu X; Wu CY; Tang Z; Wang H; Schnell P; Wan Y; Wang K; Liu L; Gao Y; Sahasranaman S; Budha N
Clin Transl Sci; 2024 Mar; 17(3):e13769. PubMed ID: 38515348
[TBL] [Abstract][Full Text] [Related]
60. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
